ELECTROCORE INC (ECOR)
US28531P2020 - Common Stock
electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024
ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today...
Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion
ROCKAWAY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and...
electroCore Announces the Launch of Truvaga Plus® for General Wellness
ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company,...
electroCore Expands Intellectual Property Portfolio
electroCore Granted Two New U.S. Patents...
electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
Record full year 2023 net sales of $16.0 million increased 87% over $8.6 million for the full year 2022 Company to host conference call and webcast today,...
electroCore to Participate in Upcoming Investor Conferences
ROCKAWAY, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company,...
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024
ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company,...
electroCore Expands Intellectual Property Portfolio
ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today...
electroCore Expands Intellectual Property Portfolio
ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today...
electroCore Expands Intellectual Property Portfolio
electroCore Granted Two New U.S. Patents...
electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology
ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today...
Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023
ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company,...
electroCore Announces Third Quarter 2023 Financial Results
Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full...
Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting
Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia...
electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue
Extension maintains listing through March 17, 2026...
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today...
Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress
“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH) ...
electroCore to Announce Third Quarter Financial Results on Wednesday, November 8
ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today...
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company,...
electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference
ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company,...
electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
ROCKAWAY, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company,...
electroCore Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering
ROCKAWAY, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today...
electroCore Announces Second Quarter 2023 Financial Results
Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter 2022 Company to host a conference call and...
electroCore announces $8.1M direct offering (NASDAQ:ECOR)
Commercial-stage bioelectronic medicine and wellness company electroCore (ECOR) will issue and sell to certain institutional and accredited investors an aggregate of 1.68M shares...
electroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
ROCKAWAY, N.J., July 31, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic...
gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)
ROCKAWAY, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today...
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today...
electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC
ROCKAWAY, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company,...
electroCore forecasts Q2 revenue to jump 65% (NASDAQ:ECOR)
electroCore (ECOR) said Tuesday it expects revenue for the second quarter of 2023 to be $3.55 million, up 65% from last year.For Q2, ECOR expects to recognize revenue of about $2.1...
gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms
ROCKAWAY, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today...
TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project
ROCKAWAY, N.J., June 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today...
electroCore to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC
ROCKAWAY, N.J., June 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company,...
electroCore Announces Poster to be Presented at the American Headache Society’s 65th Annual Scientific Meeting
ROCKAWAY, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company,...